NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical… EP News Bureau Jul 25, 2024 According to GlobalData, NewAmsterdam’s obicetrapib is expected to be the most promising agent to launch in the dyslipidemia…
